These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21845840)

  • 1. [Current status and trends in blood biologicals].
    Wang Z; Zhao X; Lv M; Zhang J
    Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):730-46. PubMed ID: 21845840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical importance of human plasma proteins and their future development].
    Schwick HG
    Beitr Infusionsther; 1991; 28():115-23. PubMed ID: 1725608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recombinant plasma proteins for therapeutic use--status and developmental trends].
    Storch H
    Beitr Infusionsther; 1993; 31():31-7. PubMed ID: 7693261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel products for haemostasis.
    Shima M; Hermans C; de Moerloose P
    Haemophilia; 2014 May; 20 Suppl 4():29-35. PubMed ID: 24762272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma-derived biological medicines used to promote haemostasis.
    Ofosu FA; Freedman J; Semple JW
    Thromb Haemost; 2008 May; 99(5):851-62. PubMed ID: 18449414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant plasma proteins.
    Burnouf T
    Vox Sang; 2011 Jan; 100(1):68-83. PubMed ID: 21175657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Traceability of drugs derived from blood: regulation and pharmaco-economic implications after 24 months of application in Paris CHU].
    Lesne-Hulin A; Bourget P; Silvie M; Barath V; Singlas E
    Pathol Biol (Paris); 1997 Nov; 45(9):741-50. PubMed ID: 9538473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotechnology: alternatives to human plasma-derived therapeutic proteins.
    Lynch TJ
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):669-88. PubMed ID: 11102283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of inherited coagulation disorders.
    Escobar MA
    Haemophilia; 2013 Sep; 19(5):648-59. PubMed ID: 23600951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioneering designs for recombinant coagulation factors.
    Schulte S
    Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel products for haemostasis - current status.
    Oldenburg J; Albert T
    Haemophilia; 2014 May; 20 Suppl 4():23-8. PubMed ID: 24762271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma protein therapies: current and future perspectives.
    Farrugia A; Robert P
    Best Pract Res Clin Haematol; 2006; 19(1):243-58. PubMed ID: 16377552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New high-technology products for the treatment of haemophilia.
    Pipe SW; Saint-Remy JM; Walsh CE
    Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors.
    Berntorp E; Figueiredo S; Futema L; Pock K; Knaub S; Walter O; Trawnicek L; Römisch J
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):577-83. PubMed ID: 20644466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease.
    Josephson CD; Abshire TC
    Best Pract Res Clin Haematol; 2006; 19(1):35-49. PubMed ID: 16377540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.